Clinical Trial Update: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This clinical trial update reports results from a Phase 3 study comparing tarlatamab to standard-of-care chemotherapy in relapsed small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Cancer (SCLC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-05